Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis - PubMed (original) (raw)
Clinical Trial
. 2003 Apr;124(4):889-93.
doi: 10.1053/gast.2003.50156.
Affiliations
- PMID: 12671884
- DOI: 10.1053/gast.2003.50156
Clinical Trial
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis
Darrell S Pardi et al. Gastroenterology. 2003 Apr.
Abstract
Background & aims: Ursodeoxycholic acid (UDCA) has shown effectiveness as a colon cancer chemopreventive agent in preclinical studies. In addition, a recent report suggests that it also may decrease the risk for developing colorectal dysplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We sought to evaluate the effect of UDCA on colorectal neoplasia in a group of patients with UC and PSC enrolled in a randomized, placebo-controlled trial.
Methods: From a prior, randomized, placebo-controlled trial of UDCA therapy in PSC at our center, we followed-up patients with concomitant UC to assess the effect of UDCA on the development of colorectal dysplasia and cancer as compared with placebo.
Results: Fifty-two subjects were followed-up for a total of 355 person-years. Those originally assigned to receive UDCA had a relative risk of 0.26 for developing colorectal dysplasia or cancer (95% confidence interval, 0.06-0.92; P = 0.034). Many of the patients originally assigned to the placebo group eventually received open-label UDCA. Assigning these patients to the UDCA group from the time they began active therapy did not change the magnitude of the protective effect (relative risk, 0.26; 95% confidence interval, 0.07-0.99; P = 0.049).
Conclusions: UDCA significantly decreases the risk for developing colorectal dysplasia or cancer in patients with UC and PSC.
Comment in
- Ursodiol: good drug makes good.
Brentnall TA. Brentnall TA. Gastroenterology. 2003 Apr;124(4):1139-40. doi: 10.1053/gast.2003.50181. Gastroenterology. 2003. PMID: 12671906 Review. No abstract available. - UC for UC: ursodiol chemoprevention for ulcerative colitis.
Brentnall T. Brentnall T. Inflamm Bowel Dis. 2003 Sep;9(5):338. doi: 10.1097/00054725-200309000-00010. Inflamm Bowel Dis. 2003. PMID: 14570007 No abstract available.
Similar articles
- The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM, Rybicki LA, Lashner BA. Wolf JM, et al. Aliment Pharmacol Ther. 2005 Nov 1;22(9):783-8. doi: 10.1111/j.1365-2036.2005.02650.x. Aliment Pharmacol Ther. 2005. PMID: 16225486 - High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, Sandberg-Gertzén H, Sangfelt P, Rydning A, Folvik G, Gangsøy-Kristiansen M, Danielsson A, Bergquist A. Lindström L, et al. Aliment Pharmacol Ther. 2012 Feb;35(4):451-7. doi: 10.1111/j.1365-2036.2011.04966.x. Epub 2012 Jan 5. Aliment Pharmacol Ther. 2012. PMID: 22221173 Clinical Trial. - Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Tung BY, et al. Ann Intern Med. 2001 Jan 16;134(2):89-95. doi: 10.7326/0003-4819-134-2-200101160-00008. Ann Intern Med. 2001. PMID: 11177311 - Ulcerative colitis and an abnormal cholangiogram.
Nguyen DL, Lazaridis KN. Nguyen DL, et al. Cleve Clin J Med. 2011 May;78(5):306-11. doi: 10.3949/ccjm.78a.10089. Cleve Clin J Med. 2011. PMID: 21536825 Review. No abstract available. - [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM, Schrumpf E. Boberg KM, et al. Tidsskr Nor Laegeforen. 1997 Sep 30;117(23):3370-3. Tidsskr Nor Laegeforen. 1997. PMID: 9411890 Review. Norwegian.
Cited by
- Cholesterol in colorectal cancer: an essential but tumorigenic precursor?
He X, Lan H, Jin K, Liu F. He X, et al. Front Oncol. 2023 Nov 3;13:1276654. doi: 10.3389/fonc.2023.1276654. eCollection 2023. Front Oncol. 2023. PMID: 38023258 Free PMC article. Review. - Post-Transplant Rectal Lymphoma After Subtotal Colectomy for Lynch Syndrome-Associated Colorectal Adenocarcinoma.
Meyer MM, Levine EJ, Kirkpatrick RB, Yearsley MM. Meyer MM, et al. Gastroenterol Hepatol (N Y). 2009 Sep;5(9):633-636. Gastroenterol Hepatol (N Y). 2009. PMID: 37967398 Free PMC article. No abstract available. - Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis.
Fu Q, Liao H, Li Z, Chen X, Zhang X, Di J. Fu Q, et al. Arch Med Sci. 2023 Jun 21;19(5):1428-1445. doi: 10.5114/aoms/167480. eCollection 2023. Arch Med Sci. 2023. PMID: 37732038 Free PMC article. Review. - Current Therapeutics in Primary Sclerosing Cholangitis.
Tan N, Lubel J, Kemp W, Roberts S, Majeed A. Tan N, et al. J Clin Transl Hepatol. 2023 Oct 28;11(5):1267-1281. doi: 10.14218/JCTH.2022.00068S. Epub 2023 Apr 17. J Clin Transl Hepatol. 2023. PMID: 37577219 Free PMC article. Review. - Current Therapies for Cholestatic Diseases.
Méndez-Sánchez N, Coronel-Castillo CE, Ordoñez-Vázquez AL. Méndez-Sánchez N, et al. Biomedicines. 2023 Jun 15;11(6):1713. doi: 10.3390/biomedicines11061713. Biomedicines. 2023. PMID: 37371808 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical